Analysis of adverse drug reactions of Denosumab (Prolia) in osteoporosis based on FDA adverse event reporting system (FAERS)
Authors:
Open Access
- 10 June 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1358592
Abstract
Objective: To comprehensively analyze the ADRs associated with Denosumab (Prolia) in the treatment of osteoporosis using data from the FAERS database, and gain a better understanding of the potential risks and side effects of Denosumab (Prolia) therapy.Methods: Data of Denosumab (Prolia) were collected from the FAERS database covering the period from first quarter of 2010 to the third quarter of 2023. Disproportionality analysis was performed by calculating the reporting odds ratios (ROR), proportional reporting ratio (PRR), and Bayesian analysis confidence propagation neural network (BCPNN) to detect positive signals.Results: Totally, 17,985,365 reports were collected from the FAERS database, 1,97,807 reports of Denosumab (Prolia) were identified as the “primary suspected (PS)” ADRs. Denosumab (Prolia) induced ADRs occurred in 27 organ systems. 38 significant disproportionality PTs satisfying with the three algorithms were retained at the same time. Unexpected significant ADRs such as bone density abnormal and immobile also occur. The majority of the ADRs occurred within the first 30 days after Denosumab (Prolia) initiation.Conclusion: Based on the American FAERS database, the high frequency ADRs of Denosumab (Prolia) were hypocalcaemia, bone density abnormal, eczema, rebound effect, spinal deformity, etc. Clinical use of this drug should focus on this part of ADRs. Attention should also be paid to newly discovered ADRs, such as immobile, menopausal symptoms, etc., to avoid more serious consequences. Cohort studies, more detailed and comprehensive case information, and long-term clinical investigations are needed to confirm these results and to further understand the safety profile of Denosumab (Prolia).Keywords
This publication has 24 references indexed in Scilit:
- Neuropsychiatric adverse reactions in patients treated with denosumab: two case reports and a review of data from the FDA Adverse Event Reporting System (FAERS)Osteoporosis International, 2023
- A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinibScientific Reports, 2022
- Prevalence of Osteoporosis and Fracture in ChinaJAMA Network Open, 2021
- OsteoporosisThe Lancet, 2019
- Denosumab‐associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital settingPharmacoepidemiology and Drug Safety, 2016
- Clinician’s Guide to Prevention and Treatment of OsteoporosisOsteoporosis International, 2014
- Postmarketing safety of biologics and biological devicesThe Spine Journal, 2014
- Denosumab for the Treatment of Osteoporosis and Cancer-Related ConditionsClinical Pharmacology & Therapeutics, 2011
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- Osteoporosis Prevention, Diagnosis, and TherapyJAMA, 2001